Akso Health Group, originally founded as the peer-to-peer lender Hexindai, has undergone multiple business pivots and currently operates primarily as a digital marketing and social e-commerce company in China. Its core business revolves around the Xiaobai Maimai app, an affiliate marketing platform that refers users to major third-party e-commerce sites and service providers. The company generates revenue by earning commissions on successful referrals and purchases, subsequently rewarding its users with a portion of these commissions. As of recent financial reports, 100% of the company's operating revenue is derived from marketing promotion services, specifically from lead generation and affiliate commissions for insurance broker agencies.
In addition to its core marketing business, Akso Health Group has been attempting to diversify into the healthcare sector. The company previously engaged in the distribution of medical devices, such as defibrillators and COVID-19 antigen tests, though this segment's revenue has recently dropped to zero. More recently, Akso has acquired equity interests in online clinics, such as Tianjin Deyihui Internet Hospital, to provide virtual medical consultations and chronic disease management in China. The company has also announced exploratory initiatives to open radiotherapy oncology centers in the United States and has launched a proprietary Brain-Computer Interface (BCI) research and development program. Despite these ambitious healthcare announcements and its rebranding, the vast majority of its current operating revenue remains concentrated in its digital marketing and affiliate promotion services. The company operates in a highly competitive and regulatory-sensitive environment, relying heavily on its ability to maintain partnerships with insurance brokers and e-commerce platforms to sustain its marketing revenue.
